|
Post by sla55 on Nov 19, 2017 8:35:24 GMT -5
|
|
|
Post by therealisaching on Nov 19, 2017 8:51:26 GMT -5
"We can tell you in the first week of the TV ad, Google search AdWords are up, website hits are up fourfold, copay downloads are up. So we can tell you all the early metrics that would indicate it's working" - Mike C
|
|
|
Post by promann on Nov 19, 2017 8:58:27 GMT -5
Great interview and wow Mike C had the insight to sell his MNKD shares when the Sanofi partnership was announced. He sees the worst behind us and we shall see what Afrezza does in these 2 next quarters.
|
|
|
Post by sayhey24 on Nov 19, 2017 9:01:17 GMT -5
That was IMO a great article. Mike said many things which have been said on this board and is 100% in on making MNKD great.
I thought it was an interesting comment as it matches what Onduo will be hitting the streets with
"we're open to a co-promote partner, which means you would take another large company's 300 to 500 reps, and you would drop this in their bag as a secondary position. And now we can train them and do a lot better." onduo.com
|
|
|
Post by liane on Nov 19, 2017 9:05:11 GMT -5
Great interview! Very polished and candid. I too was amazed that he owned MNKD, and then sold on the SNY partnership. Go Mike!
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Nov 19, 2017 9:12:32 GMT -5
"With the financing we got, it gave us extra breathing room to turn on TV and make some bigger decisions as we go forward. But at this point, it's purely an investment of scale-up discussion. This isn't about will the drug succeed or not, will the company be in bankruptcy or not. I don't see those things happening at this point. The drug will succeed. The company is not heading for bankruptcy. So it's really a matter of are we going to be $50 million, $100 million, or $500 million. And I think those trends over the next six months will really start to show people what can happen."
|
|
|
Post by peppy on Nov 19, 2017 9:48:52 GMT -5
quote: So when it came to making decisions around pricing and managed care strategies and reimbursement
quote: It's [Afrezza] not like regular insulin. They tried to think about how to use sub-q [subcutaneous] insulin and said, "I know how to use sub-qs; that's how I'll use Afrezza." And it's a different product. It's got different dosing. You use it at mealtime, but it's not a 1-to-1 ratio. I think that the No. 1 mistake that they made out the door was not talking about the PK/PD [pharmacokinetics/pharmacodynamics] and the difference -- how you would think about the dosing and titrating up.
quote: I have expressed publicly that we're open to a co-promote partner. To me, this is our lead asset.
*quote: But there are a lot of patients, and that's where a lot of them sit -- in the type 2 market. So as we continue to expand and fix coverage, and the package is now fixed, we're open to a co-promote partner, which means you would take another large company's 300 to 500 reps, and you would drop this in their bag as a secondary position. And now we can train them and do a lot better.
*REPLY: unit pricing is going to present a problem here. unless we catch them early and try to give the pancreas beta cells a rest. it may all be about the phase one here? the medical model needs to be turned upside down for physicians to prescribe mealtime insulin as an early response type two.
---------------------------------------------------------------------------------------------------------- Speights: You announced the upcoming stockholder meeting on authorizing around 140 million new shares. Why that number? Do you anticipate any pushback or difficulty getting the authorization approved?
Castagna: The purpose of the 140 million --- there is no right or wrong number. You could have went for 20 million. you could have went for 200 million. There are 140 million outstanding shares now, so we're just increasing that count to 280 million. The reality is that if you want to make an acquisition, you have to have shares. If you want to continue to expand the company, you might need shares available to do things. To do partnerships, you could need shares, to bring in an ownership in the company.
So we only have 4 million shares left. That's not in the interest of shareholders to run a company and have zero options on the table if things pop up over the next two to three years. So what I didn't want to do, honestly, is say I want 20 million shares and everybody says, "Oh, we have 10% dilution coming." You needed to have a number that was reasonable but not too absurd. I think that's what's important.
|
|
|
Post by sportsrancho on Nov 19, 2017 10:08:46 GMT -5
EMBED Nov. 19 at 6:27 AM BigCheeze Cheese Head
$MNKD I think Castanga got the message loud and clear from us and provided clarity and guidance I was looking for.I AM GOING TO VOTE YES.
|
|
|
Post by thekindaguyiyam on Nov 19, 2017 12:13:40 GMT -5
Speaking in the kindest way about Sanofi and saying he sold his shares (before he became CEO) when Sanofi partnered; expresses a non-aggressive representation of Sanofi and tells us that he values Mannkind representing itself. In this; he was a diplomat with our past partner and then went over the top to say how he liked the Motley Fool. Wow. Not if that's not a handshake with a media representative of short interest which has been ruthless I don't know what is. In expressing no negatives (as being a viciim) this interview was nothing but Positive address the potential of the future while giving confidence to investors.
|
|
|
Post by liane on Nov 19, 2017 12:18:24 GMT -5
|
|
|
Post by gamblerjag on Nov 19, 2017 13:04:08 GMT -5
first I want to say that when Mike presents in person I think he does a very good job perhaps his last conference call wasn't his best but it was still very good but where I think he really excels at is in interviews and how it's put down on paper great mF article he really addresses most everything and puts the information out there to make real long does feel great about their investment thanks Mike
|
|
|
Post by sportsrancho on Nov 19, 2017 13:15:25 GMT -5
Mike lost his father to diabetes, he never even knew him. He was a shareholder, just like us, because he believed in Afrezza and Al’s vision. He wasn’t just looking for a company to turn around, he believed in all the same things we do as shareholders! Just had to add that to the ( he was smart and got out when SNY got in! :-) And now he’s back in.....all in!
|
|
|
Post by thekindaguyiyam on Nov 19, 2017 14:30:25 GMT -5
His confidence in Afrezza and Mannkind .. a kind of maturing in assuming a position of Equal rather than oppressed. We are clearly in a new chapter as he expressed himself from strength.
|
|
|
Post by mnholdem on Nov 19, 2017 14:35:19 GMT -5
As I understand it, much of Mike's time was consumed for the last few months working with Steve on re-capitalizing. Absolutely necessary and understood, but it's really good to see him out and about again promoting MannKind and Afrezza. While I agree that he was "diplomatic" in his remarks about Sanofi, I thought the CEO's remarks about Afrezza's path to success were intended to inform and attract Wall Street investors and analysts. I notice that other Wall Street publications have already reprinted the interview and I think more will follow.
|
|
|
Post by sportsrancho on Nov 19, 2017 14:37:58 GMT -5
CEO of Maredin Capital
|
|